Recursion Pharmaceuticals Inc. Class A Common Stock (RXRX)
Stock · NASDAQ · Health Care
$3.46as of 10/16/2026
Price chart
Active signals
RXRX Signal Track Record
How signals performed across all stocks →What RXRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | -3.9% | 44% | October 5, 2026 |
| Bollinger Band Breakout | 23 | -4.9% | 39% | October 5, 2026 |
| Bollinger Band BreakdownActive now | 18 | -6.2% | 44% | May 13, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -9.8% | 24% | September 4, 2026 |
| Any 20-session window (baseline) | -2.3% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RXRX
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 600
- Website
- www.recursion.com/
Fundamentals
- 1-day range
- $3.49$4.19
- Market cap
- $1.69B
- P/E (trailing)
- —
- P/E (forward)
- -3.94
- EPS (trailing)
- $-1.04
- Dividend yield
- —
- Beta
- 1.18
- Avg. volume
- 21.17M
How Recursion Pharmaceuticals Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Recursion Pharmaceuticals Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- RXRXRecursion Pharmaceuticals Inc. Class A Common Stock$3.46▼ 16.71%Market cap $1.69BP/E —$2.77$7.18
- IMCRImmunocore Holdings plc American Depositary Shares$29.4▼ 0.27%Market cap $1.66BP/E —$27.5$40.71
- MAZEMaze Therapeutics Inc. Common Stock$27.53▲ 0.18%Market cap $1.58BP/E —$21.95$53.65
- TSHATaysha Gene Therapies Inc. Common Stock$3.62▼ 2.95%Market cap $1.82BP/E —$3.46$7.3
- SLBTSL Science Holding Limited Ordinary Shares$1.53▼ 1.29%Market cap $1.53BP/E —$1.42$14.5
- VIRVir Biotechnology Inc. Common Stock$9.96▼ 4.87%Market cap $1.48BP/E —$4.82$12
- MESOMesoblast Limited American Depositary Shares$13.28▼ 4.80%Market cap $2.02BP/E —$1.88$3.31
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals Inc. Class A Common Stock | $1.69B | — | $3.46 | ▼ 16.71% | $2.77$7.18 |
| IMCR Immunocore Holdings plc American Depositary Shares | $1.66B | — | $29.4 | ▼ 0.27% | $27.5$40.71 |
| MAZE Maze Therapeutics Inc. Common Stock | $1.58B | — | $27.53 | ▲ 0.18% | $21.95$53.65 |
| TSHA Taysha Gene Therapies Inc. Common Stock | $1.82B | — | $3.62 | ▼ 2.95% | $3.46$7.3 |
| SLBT SL Science Holding Limited Ordinary Shares | $1.53B | — | $1.53 | ▼ 1.29% | $1.42$14.5 |
| VIR Vir Biotechnology Inc. Common Stock | $1.48B | — | $9.96 | ▼ 4.87% | $4.82$12 |
| MESO Mesoblast Limited American Depositary Shares | $2.02B | — | $13.28 | ▼ 4.80% | $1.88$3.31 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Knowbenzinga · 10/16/2026
- 'HHS launches project to speed up clinical trials' - AxiosBenzinga · 9/30/2026
- Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical ProgressSeekingAlpha · 9/29/2026
- Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to NoteYahoo · 9/28/2026
- Squeeze Watch: 10 Stocks With Over 33% Short InterestBenzinga · 9/25/2026
- Analysts move HubSpot 29 places higher in power rankingYahoo · 9/24/2026
- Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?Yahoo · 9/24/2026
- Enveda secures $311M to bring more nature-derived AI drugs into clinical trialsYahoo · 9/23/2026
- Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should KnowYahoo · 9/22/2026
Insider Activity
Insider Actions →- Zavain Dar · October 1, 2026 · Grant4.6K
- Dean Y. Li · October 1, 2026 · Grant3.4K
- Ben R. Taylor · September 15, 2026 · Tax Withholding5.4K @ $3.41
- Najat Khan · September 8, 2026 · Sale22.4K @ $3.52
- Blake Borgeson · September 1, 2026 · Sale30.0K @ $3.34
- Najat Khan · August 17, 2026 · Tax Withholding80.5K @ $3.16
- David Hallett · August 17, 2026 · Tax Withholding26.7K @ $3.16
- Ben R. Taylor · August 17, 2026 · Tax Withholding25.0K @ $3.16
- Blake Borgeson · August 4, 2026 · Sale30.0K @ $3.25
- Blake Borgeson · July 7, 2026 · Sale40.0K @ $3.96
- Zavain Dar · July 1, 2026 · Grant5.1K
- Dean Y. Li · July 1, 2026 · Grant3.7K
- Namandje Bumpus · June 18, 2026 · Sale4.0K @ $3.18
- Blake Borgeson · June 17, 2026 · Grant88.4K
- Franziska Michor · June 17, 2026 · Grant88.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 315.01M
- Total value held
- $959.52M
- Institutional holders
- 332
- Unknown43.19M
- Unknown40.21M
- Unknown28.49M
- Unknown23.68M
- Unknown22.24M
- Unknown13.64M
- Unknown12.28M
- Unknown9.64M
- Unknown8.39M
- Unknown6.07M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Recursion Pharmaceuticals Stock Falls as Cathie Wood Adjusts Biotech Holdings
Recursion Pharmaceuticals shares have declined recently while the broader market improved. This movement coincides with Cathie Wood's recent portfolio adjustments, where she increased positions in several biotech stocks while reducing others. The stock is currently trading near the middle of its 52-week range, with analysts maintaining an average target price of $7.22.
Recursion Pharmaceuticals Stock Falls as Cathie Wood Adjusts Biotech Holdings. Recursion Pharmaceuticals shares have declined recently while the broader market improved. This movement coincides with Cathie Wood's recent portfolio adjustments, where she increased positions in several biotech stocks while reducing others. The stock is currently trading near the middle of its 52-week range, with analysts maintaining an average target price of $7.22.